Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
A GnRH decapeptide delivered as a subcutaneous depot implant.
Also known as: Zoladex
Part of the Foundational & therapeutic peptides cluster
Overview
Goserelin is a synthetic decapeptide GnRH agonist that suppresses gonadal sex-hormone production through non-pulsatile receptor stimulation. It is an approved therapeutic for hormone-responsive breast and prostate cancers and several benign gynecologic conditions. Content here is educational only.
Source & context
Biological / chemical source: Synthetic decapeptide analog of GnRH
Primary research or clinical context: Approved for breast and prostate cancer, endometriosis and assisted reproduction
Depot implant design
Goserelin is formulated as a biodegradable implant injected under the skin, releasing peptide slowly over one to three months. This delivery approach solves the short half-life problem common to peptide hormones and is a classic example of sustained-release peptide engineering.
Endocrine effect
By overriding the normal pulsatile GnRH rhythm, goserelin drives the pituitary into down-regulation, reducing testosterone in men and estrogen in women. It is studied and used across oncology, endometriosis, fibroids and fertility protocols.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Goserelin (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C59H84N18O14
- Average reference mass
- ≈ 1,269.4
- Status
- Approved medicine in at least one jurisdiction (IUPHAR record)
N-terminal residue is pyroglutamic acid; serine residue is 1,1-dimethylethyl-serine
- PubChem CID: 5311128
- IUPHAR ligand: 3879
- ChEMBL: CHEMBL1201247
- DrugBank: DB00014
- CAS RN: 65807-02-5
- UNII: 0F65R8P09N
Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 416 registered studies with “Goserelin” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT07460752 | Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and | Phase 2 | recruiting | 2026-10-01 |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Can | Phase 3 | active not recruiting | 2026-10-01 |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | Phase 4 | active not recruiting | 2026-10-01 |
| NCT05827081 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | recruiting | 2026-10-01 |
| NCT01492972 | Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer | Phase 3 | recruiting | 2026-09-29 |
| NCT04325828 | A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gla | Phase 2 | active not recruiting | 2026-09-25 |
Goserelin — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Goserelin (source record; form not independently established)Average reference mass: 1,269.4 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Goserelin
What is Goserelin?+
Goserelin is a synthetic decapeptide GnRH agonist that suppresses gonadal sex-hormone production through non-pulsatile receptor stimulation. It is an approved therapeutic for hormone-responsive breast and prostate cancers and several benign gynecologic conditions. Content here is educational only.
What Canadian product status is recorded for Goserelin?+
Canadian product status for Goserelin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Goserelin?+
Goserelin is commonly described as approximately 10 amino acids (GnRH agonist).
Related peptides
References & further reading
- 1.Moghissi et al. (1998). Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril
- 2.Mitchell (2004). Goserelin ('Zoladex')--offering patients more choice in early breast cancer. Eur J Oncol Nurs
- 3.Gu et al. (2023). Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial. Chin Med J (Engl)
- 4.West et al. (1992). Goserelin (Zoladex) in the treatment of fibroids. Br J Obstet Gynaecol
- 5.Cockshott (2000). Clinical pharmacokinetics of goserelin. Clin Pharmacokinet
- 6.Nygård et al. (2001). Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis. Anticancer Res
- 7.Reichel et al. (1992). Goserelin (Zoladex) depot in the treatment of endometriosis. Zoladex Endometriosis Study Group. Fertil Steril
- 8.Klarskov et al. (1990). [Goserelin]. Ugeskr Laeger
- 9.PubChem — compound summary for Goserelin (CID 5311128)
- 10.Wikipedia — Goserelin